Six patients with necrotizing vasculitis were treated with oral colchicine as part of an open study. Four patients with cutaneous vasculitis and normal levels of serum complement and one patient with vasculitis associated with Behçet's syndrome demonstrated clinical improvement while receiving colchicine. One patient with cryoglobulinemia, hypocomplementemia, and cutaneous vasculitis showed no response to colchicine therapy. In three patients, clinical improvement persisted after its withdrawal. Colchicine may be effective in controlling cutaneous necrotizing vasculitis and Behçet's syndrome through its effect on polymorphonuclear leukocyte function.
(Arch Dermatol 115:1303-1306, 1979)
Hazen PG, Michel B. Management of Necrotizing Vasculitis With Colchicine: Improvement in Patients With Cutaneous Lesions and Behçet's Syndrome. Arch Dermatol. 1979;115(11):1303–1306. doi:10.1001/archderm.1979.04010110009014
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: